Table 3.
Baseline Characteristics of 526 High‐risk Patients According to Ln_RH‐PAT Ratio
| Ln_RH‐PAT Ratio | P Value | ||
|---|---|---|---|
| High Ln_RH‐PAT Ratio 0.246< (n=263) | Low Ln_RH‐PAT Ratio ≤0.246 (n=263) | ||
| Age, mean (SD), y | 66.3 (11.3) | 68.0 (10.0) | 0.068 |
| Male sex, no. (%) | 174 (66.2) | 190 (72.2) | 0.156 |
| Body mass index, mean (SD), kg/m2 | 23.8 (3.5) | 24.5 (3.4) | 0.024 |
| Hypertension, no. (%) | 204 (77.6) | 223 (84.8) | 0.044 |
| Diabetes, no. (%) | 125 (47.5) | 121 (46.0) | 0.793 |
| Dyslipidemia, no. (%) | 214 (81.4) | 223 (84.8) | 0.352 |
| Current smoking, no. (%) | 48 (18.3) | 64 (24.3) | 0.110 |
| Family history of CAD, no. (%) | 75 (28.5) | 55 (20.9) | 0.055 |
| Systolic BP, mean (SD), mm Hg | 128.5 (18.6) | 129.9 (18.0) | 0.377 |
| Diastolic BP, mean (SD), mm Hg | 72.3 (12.4) | 72.9 (11.6) | 0.547 |
| Hemoglobin A1c, mean (SD), % | 6.4 (1.0) | 6.4 (1.1) | 0.794 |
| Total/HDL cholesterol ratio, mean (SD) | 3.5 (1.0) | 3.8 (1.1) | 0.008 |
| LDL cholesterol, mean (SD), mg/dL | 104.5 (31.5) | 106.0 (31.7) | 0.595 |
| HDL cholesterol, mean (SD), mg/dL | 53.4 (14.2) | 50.4 (14.6) | 0.016 |
| Triglycerides, median (IQR), mg/dL | 114 (78 to 150) | 119 (87 to 161) | 0.100 |
| LVEF, mean (SD), % | 63.8 (7.3) | 63.5 (6.5) | 0.647 |
| BNP, median (IQR), pg/mL | 28.0 (11.2 to 56.8) | 28.0 (14.7 to 63.2) | 0.183 |
| hsCRP, median (IQR), mg/L | 0.70 (0.30 to 1.90) | 0.80 (0.38 to 1.70) | 0.479 |
| eGFR, mean (SD), mL/min per 1.73 m2 | 68.7 (17.6) | 65.9 (18.6) | 0.076 |
| Aspirin, no. (%) | 202 (76.8) | 231 (87.8) | 0.001 |
| HMG‐CoA RIs, no. (%) | 176 (66.9) | 196 (74.5) | 0.068 |
| CCB, no. (%) | 151 (57.4) | 154 (58.6) | 0.792 |
| ACE‐I or ARB, no. (%) | 140 (53.2) | 155 (58.9) | 0.219 |
| β‐blockers, no. (%) | 103 (39.2) | 124 (47.1) | 0.078 |
| Anti‐diabetic drugs, no. (%) | 86 (32.7) | 87 (33.1) | >0.99 |
| Coronary artery disease, no. (%) | 191 (72.6) | 249 (94.7) | <0.0001 |
| FRS, median (IQR), % | 7.0 (2.0 to 11.0) | 9.0 (6.0 to 11.0) | <0.0001 |
| SYNTAXsc, median (IQR) | 11.0 (0.0 to 19.0) | 15.0 (7.0 to 22.0) | <0.0001 |
| SYNTAXsc ≥23, no. (%) | 39 (14.8) | 52 (19.8) | 0.166 |
| Ln_RH‐PAT ratio, mean (SD) | 0.490 (0.213) | 0.094 (0.105) | <0.0001 |
| Cardiovascular events, no. (%) | 29 (11.0) | 75 (28.5) | <0.0001 |
Data are the mean (SD), median values (25th to 75th percentile range), or no. (%). Significance was assessed by an unpaired t test, the Mann‐Whitney U test or Fisher's exact test. ACE‐I indicates angiotensin‐converting enzyme‐inhibitors; ARB, angiotensin II receptor blockers; BNP, B‐type natriuretic peptide; BP, blood pressure; CAD, coronary artery disease; CCB, calcium channel blockers; eGFR, estimated glomerular filtration rate; FRS, Framingham Risk Score; HDL, high‐density lipoprotein; HMG‐CoA RIs, hydroxymethylglutaryl‐CoA reductase inhibitors; hsCRP, high‐sensitivity C‐reactive protein; IQR, interquartile range; LDL, low‐density lipoprotein; LVEF, left ventricular ejection fraction; RH‐PAT, reactive hyperemia‐peripheral arterial tonometry; SD, standard deviation; SYNTAXsc, Synergy Between PCI With Taxus and Cardiac Surgery score.